The companies can now offer marketing and commercialization rights for Ondansetron ODF in Europe and selected Non-European countries, either through global, regional or local license agreements.
Ondansetron ODF is indicated for the prevention and treatment of chemotherapy and radiotherapy induced nausea and vomiting (CINV and RINV) in adults as well as children aged equal or above 6 months, and the prevention and treatment of post operative nausea and vomiting (PONV) in adults and children aged equal or above 4 years.
APR and Labtec have developed Ondansetron ODF as an ‘orodispersible film’ form in collaboration with Monosol RX.
The companis claim the Ondansetron ODF formulation with Rapidfilm technology, a proprietary oral drug delivery technology platform, improves patient compliance by reducing swallowing difficulties.
APR CEO Paolo Galfetti said they are now looking for commercial partners in the various countries of continental Europe with the right sale organization and marketing infrastructure able to maximize the product sale potential.